On December 19, 2019, the shipment of the NEW antihypertensive drug NEBIVOLO-NAN, manufactured by the State Enterprise “ACADEMPHARM”, began. Nebivolol-NAN is a highly selective third-generation Beta1-adrenergic blocker that provides an additional vasodilator effect by modulating the release of an endothelium-dependent relaxing factor for the treatment of arterial hypertension and heart failure.
Dosage and packing: 5 mg No. 30
The main characteristics of the new drug:
- Improves the quality of life of patients with hypertension
- Well tolerated
- Does not reduce physical performance
- Does not affect sexual performance